Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF G469R |
Therapy | Dabrafenib + Trametinib |
Indication/Tumor Type | large cell neuroendocrine carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF G469R | large cell neuroendocrine carcinoma | predicted - sensitive | Dabrafenib + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in a durable response in a patient with large cell neuroendocrine carcinoma of the lung harboring BRAF G469R, along with ERBB4 (HER4) A118S, STK11 L282fs, TP53 R248L and MYC amplification and led to a decrease in BRAF G469R in cell-free DNA (PMID: 35135105). | 35135105 |
PubMed Id | Reference Title | Details |
---|---|---|
(35135105) | Large-Cell Neuroendocrine Carcinoma of the Lung: A Focused Analysis of BRAF Alterations and Case Report of a BRAF Non-V600-Mutated Tumor Responding to Targeted Therapy. | Full reference... |